MedCity News April 4, 2024
Katie Adams

Chicago-based Prenosis gained FDA clearance for its sepsis detection technology this week, marking the first time the agency has cleared an AI diagnostic tool for sepsis.

This week, Prenosis gained FDA clearance for its sepsis detection technology — marking the first time the agency has cleared an AI diagnostic tool for sepsis.

Chicago-based Prenosis was founded in 2014 with “a mission to bring precision medicine to acute care,” said CEO and Co-founder Bobby Reddy in an interview.

“We want each patient in the hospital to be treated based on their biology,” he explained. “We realized that, unfortunately, a lot of the technology in hospitals is focused around protocols — meaning that you would treat a patient that is 25 years...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Provider, Technology
Related Articles:
FDA targets health inequality by improving at-home devices
STAT+: FDA is criticized for taking a ‘ministerial’ role in sorting out some pharma patents
We now know Tome’s gene editing target
STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more
FDA Updates for the Week of May 6: An Approval, a Delay and Two Ad Comm Meetings

Share This Article